Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
Rhea-AI Summary
Adia Nutrition (OTC Pink: ADIA) announces global expansion plans for its subsidiary Adia Med following strong international interest. The company has received multiple inquiries from healthcare organizations worldwide interested in establishing clinics offering their advanced treatments.
Key developments include:
- Legal clearance received for international expansion
- Specific location identified outside the US for first international clinic
- Focus on cutting-edge treatments including Therapeutic Plasma Exchange, Hematopoietic Stem Cell Transplantation, and umbilical cord blood stem cell therapies
- Featuring their premier product Adia Vita, known for high potency and purity in regenerative medicine
Adia Med stands as one of only three clinic networks in the US with specialized technology for these treatments. CEO Larry Powalisz confirms they are actively pursuing international opportunities while ensuring compliance with global healthcare standards. The expansion aims to bring their innovative therapies, particularly the sought-after Adia Vita treatment, to patients worldwide.
Positive
- Global expansion potential with multiple international organizations expressing interest in Adia Med's treatments
- Legal clearance received for international operations, confirming feasibility of global expansion
- Specific international location already identified for first expansion
- Company offers unique treatments including TPE and HSCT, being one of only three clinic networks in US with this technology
- Strong market positioning with proprietary Adia Vita product gaining international recognition
Negative
- International expansion still in early planning phase without concrete timeline
- Regulatory requirements and compliance costs for international operations not yet determined
- No specific financial metrics or investment requirements disclosed for expansion plans
News Market Reaction 1 Alert
On the day this news was published, ADIA declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Winter Park, Florida--(Newsfile Corp. - March 25, 2025) - Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively exploring international expansion after receiving significant interest from multiple international groups. Over recent months, several organizations and healthcare entities from various countries have reached out to Adia Med, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and notably, umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. In response, Adia Med has begun a comprehensive review of the legalities and regulations required to bring its pioneering care to a global stage.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243471__bf477173-b44d-457c-bb35-7984f21e1815.jpg
Adia Med's leadership has taken proactive steps toward this potential expansion, consulting legal experts to evaluate the feasibility of operating clinics abroad. The company recently received a letter of opinion from its legal counsel, confirming that international expansion is permissible and providing a detailed blueprint for navigating the regulatory landscape. This legal framework outlines the steps needed to comply with international healthcare standards, setting the stage for Adia Med to extend its innovative therapies, including the highly sought-after Adia Vita, beyond the United States.
"We've been overwhelmed by the global enthusiasm for our work, particularly from groups interested in leveraging Adia Labs' Adia Vita for umbilical cord blood stem cell therapies," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering transformative treatments, and with this international outreach, we're exploring how to share our advancements, like Adia Vita, our premier stem cell product, with the world. We've already identified an appealing location outside the U.S. that we're likely to pursue, and our lawyer's guidance assures us that going international is within reach."
Adia Vita, offered by Adia Labs, has garnered attention for its unprecedented potency and purity, making it a standout in regenerative medicine. International groups have expressed keen interest in utilizing this premier UCB-SC product for therapies targeting a range of conditions, from circulatory disorders to orthopedic applications. Adia Med's expertise with apheresis machines for TPE and HSCT, combined with its leadership in UCB-SC therapies, positions it as one of only three clinic networks in the U.S. with this technology—a distinction that has fueled global curiosity.
While the expansion remains in the planning phase, Adia Med is committed to meeting this international demand by carefully assessing regulatory requirements, forging strategic partnerships, and refining its approach to ensure a smooth entry into new markets. Larry Powalisz, CEO of Adia Nutrition, shared, "We've recently pinpointed a specific location outside the US for launching our first international Adia Med," signaling a clear step toward global outreach. This move aligns with Adia Nutrition's mission to revolutionize healthcare and deliver impactful solutions worldwide, leveraging their expertise in regenerative medicine to reach new patients beyond U.S. borders.
For more information about Adia Med's current offerings, including Adia Vita, or updates on its international plans, please visit www.adiamed.com or contact ceo@adiamed.com.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243471
FAQ
What international expansion plans does Adia Nutrition (ADIA) announce in March 2025?
What treatments does Adia Med (ADIA) offer in its clinics?
How is Adia Med (ADIA) preparing for its global expansion in 2025?
What makes Adia Med's (ADIA) stem cell product Adia Vita unique?
What competitive advantage does Adia Med (ADIA) have in the US market?
